Rovin Capital UT ADV Has $61,000 Position in Geron Co. (NASDAQ:GERN)

Rovin Capital UT ADV increased its stake in shares of Geron Co. (NASDAQ:GERN) by 26.9% during the 4th quarter, Holdings Channel reports. The fund owned 17,270 shares of the biopharmaceutical company’s stock after acquiring an additional 3,660 shares during the period. Rovin Capital UT ADV’s holdings in Geron were worth $61,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Elmwood Wealth Management Inc. acquired a new stake in Geron in the fourth quarter valued at approximately $93,000. Moody National Bank Trust Division lifted its holdings in shares of Geron by 76.6% in the 4th quarter. Moody National Bank Trust Division now owns 267,629 shares of the biopharmaceutical company’s stock worth $947,000 after purchasing an additional 116,074 shares in the last quarter. Exome Asset Management LLC acquired a new stake in Geron in the 3rd quarter valued at $4,109,000. Alternative Investment Advisors LLC. increased its stake in Geron by 13.3% during the 3rd quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 2,612 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in Geron by 461.4% during the third quarter. Franklin Resources Inc. now owns 79,923 shares of the biopharmaceutical company’s stock worth $331,000 after buying an additional 65,687 shares during the last quarter. 73.71% of the stock is currently owned by institutional investors and hedge funds.

Geron Trading Down 3.0 %

NASDAQ GERN opened at $2.92 on Friday. The business’s fifty day moving average is $3.70 and its 200-day moving average is $4.19. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of -9.13 and a beta of 0.55. Geron Co. has a one year low of $1.64 and a one year high of $5.34.

Geron (NASDAQ:GERN) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.05. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The business had revenue of $28.27 million for the quarter, compared to analyst estimates of $18.97 million. During the same quarter in the previous year, the firm posted ($0.08) earnings per share. The company’s revenue for the quarter was up 17138.4% on a year-over-year basis. Equities research analysts predict that Geron Co. will post -0.25 EPS for the current year.

Analysts Set New Price Targets

GERN has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Geron in a report on Tuesday, December 10th. Needham & Company LLC boosted their price objective on Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday. Barclays upgraded Geron to a “strong-buy” rating in a report on Friday, November 29th. Finally, Scotiabank started coverage on Geron in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 price target for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.